鼻癌当前临床试验的全球差异
Carl Jay E Jainar1, Luisa E Jacomina2, Edward Christopher Dee3
1Department of Radiation Oncology, Benavides Cancer Institute, University of Santo Tomas Hospital, Manila, Philippines.
概括
鼻癌 (NPC) 临床试验在地理上没有代表性,低收入国家代表性不足. 在这些关键的试验中,放射治疗 (RT) 也没有得到充分的研究.
科学领域:
- 在瘤学瘤学.
- 临床试验 研究 研究 临床试验 临床试验
- 全球健康差距的差异
背景情况:
- 鼻癌 (NPC) 不成比例地影响东/东南亚和北非.
- 临床试验对于以证据为基础的护理至关重要,但其地理代表性尚不清楚.
- 放射治疗 (RT) 是NPC治疗的基石.
研究的目的:
- 分析NPC临床试验的地理分布.
- 评估在NPC试验中的特有国家的代表性.
- 在NPC临床试验中评估放射治疗 (RT) 的研究.
主要方法:
- 2013-2023年NPC临床试验的第二阶段和第三阶段通过ClinicalTrials.gov.gov被确定.
- 使用GLOBOCAN 2022发病率来定义特有国家.
- 试验干预和原产国被系统地分析.
主要成果:
- 分析了266项试验;50%专注于免疫疗法/向治疗,30%专注于化疗,9%专注于RT.
- 中国主导试验起源 (80%),其次是美国 (4.5%).
- 只有17%的NPC流行国家在国际试验中得到代表,而低收入国家严重不足.
结论:
- 在NPC临床试验中存在显著的地理和收入差异.
- 低收入的特有国家在研究中严重不足.
- 需要加强全球合作,包括多元化的群体和研究人员.
更多相关视频
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
11.6K
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.3K
相关概念视频
Clinical Trials: Overview
3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
Clinical Trials
8.6K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
8.6K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Bias in Epidemiological Studies
697
Biases can arise at various stages of research, from study design and data collection to analysis and interpretation. Recognizing and addressing these biases is essential to ensure the validity and reliability of epidemiological findings.Broadly speaking, biases in epidemiology fall into three main categories: selection bias, information bias, and confounding. A more detailed description of possible biases is:
697
Hazard Ratio
257
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
257
